

RESEARCH

Open Access

Haemoglobin dynamics in Papuan and non-Papuan adults in northeast Papua, Indonesia, with acute, uncomplicated vivax or falciparum malaria

Walter RJ Taylor^{1,2*}, Hendra Widjaja¹, Hasan Basri¹, Emiliana Tjitra³, Colin Ohrt⁴, Taufik Taufik⁵, Samuel Baso⁶, Stephen L Hoffman⁷ and Thomas L Richie¹

Abstract

Background: Haemoglobin (Hb) recovers slowly in malaria and may be influenced by naturally acquired immunity. Hb recovery was compared in malaria immune, indigenous Papuan and non-Papuan adults with limited malaria exposure.

Methods: Hb concentrations were measured on Days (D) 0, 3, 7, and 28 in 57 Papuans and 105 non-Papuans treated with chloroquine, doxycycline or both drugs for acute, uncomplicated *Plasmodium vivax* (n = 64) or *Plasmodium falciparum* (n = 98).

Results: Mean (SD, range) D0 Hb was 12.7 (2.2, 7–21.3) g/dL and was similar in *P. falciparum* infected Papuans and non-Papuans: 12.2 vs. 12.8 g/dL ($P = 0.15$) but significantly lower in: (i) *P. vivax*-infected Papuans vs. *P. vivax*-infected non-Papuans: 11.4 vs. 13.47 g/dL [$\Delta = -2.07$ (95% CI: -3.3 – -0.8), $P = 0.0018$], (ii) all patients with splenomegaly (vs. those without splenomegaly): 12.16 vs. 13.01 g/dL [$\Delta = -0.85$ (-1.6 – -0.085), $P = 0.029$], and (iii) all females vs. all males: 10.18 vs. 13.01 g/dL [$\Delta = -2.82$ (-3.97 – -1.67), $P < 0.0001$]. Multiple regression identified female sex ($P = 0.000$), longer illness duration ($P = 0.015$) (*P. falciparum* patients) and Papuan ethnicity ($P = 0.017$) (*P. vivax* patients) as significant factors for a lower D0 Hb.

Mean D28 Hb increased to 13.6 g/dL [$\Delta = 1.01$ (0.5–1.5) vs. D0 Hb, $P = 0.0001$]. It was: (i) positively correlated with the D0 Hb (adjusted $R^2 = 0.24$, $P = 0.000$), and was significantly lower in *P. vivax* infected Papuans vs. non-Papuans: 12.71 vs. 14.46 g/dL [$\Delta = -1.7$ (-2.95 – -0.5, $P = 0.006$).

Conclusions: Haemoglobin recovery was related to baseline Hb. Vivax-infected malaria immune Papuans had persistently lower Hb concentrations compared to non-Papuans with limited malaria exposure. This haematological disadvantage remains unexplained.

Keywords: Anaemia, Malaria, Papuans, Indonesia

* Correspondence: bob@tropmedres.ac

¹The US Navy Medical Research Unit no. 2 (NAMRU-2), Jakarta, Indonesia

²Department of Tropical Medicine, Tulane University School of Public Health, New Orleans, USA

Full list of author information is available at the end of the article

Background

Malaria-associated anaemia is common and occurs in acute symptomatic infections, severe malaria, chronic asymptomatic infections, and inadequately treated or resistant infections [1-3]. Concomitant hookworm infestation, micronutrient deficiency, inherited blood disorders, and HIV compound the anaemic effects of malaria [4,5].

The main pathophysiological mechanisms in malaria related anaemia are the splenic removal of red cells, bone marrow suppression and dyserythropoiesis, and acute haemolytic anaemia (AHA) [1,6]. AHA may occur when parasitized red blood cells (PRBCs) are destroyed by the developing parasite and is potentially greater in *Plasmodium falciparum* because red blood cells of all ages are invaded and parasitaemia is high. *Plasmodium vivax* produces a low parasitaemia and invades only reticulocytes [7]. Malaria or drug-induced oxidant stress in patients with glucose-6-phosphate dehydrogenase deficiency may also produce AHA [8,9].

PRBCs and non-parasitized red blood cells (NPRBCs) are removed from the circulation but NPRBCs contribute much more to anaemia and this differs between the species. An estimated 34 NPRBCs in *P. vivax* [10] and eight NPRBCs in *P. falciparum* [2,11] are removed from the circulation for one PRBC. The splenic threshold for removing red cells is lowered in falciparum malaria [12] and splenic removal is directly related to spleen size [1,13]. Immune related changes to red cells results in their recognition and phagocytosis by activated monocytes and macrophages whilst others are trapped and destroyed in the splenic sinusoids [1,14]. In *P. falciparum*, NPRBCs and PRBCs have reduced deformability, making splenic trapping easier whilst, because of their increased size, vivax PRBCs have increased deformability but increased fragility, so splenic destruction is more likely [15-17]. The spleen also removes vivax (K. Chotivanich, unpublished data) and falciparum parasites from red cells and returns the deparasitized red cells back to the circulation, a process called pitting [13,18]; pitted RBCs cells also have reduced survival [19].

Depressed bone marrow function and dyserythropoiesis result in reduced red cell genesis and reticulocytopenia and poor bone marrow iron utilization is documented in *P. falciparum* despite adequate bone marrow stores [20]. Bone marrow changes may be related to cytokine imbalances in favour of raised TNF [21,22], the toxic effects of haemozoin [23], a blunted response to erythropoietin [24] and relative under-production of erythropoietin in adults [25].

With effective anti-malarial treatment, the mean haemoglobin (Hb) falls initially, reaching a nadir on Day 3 or Day 7 (most studies have collected data on these days only) and rises thereafter to stabilize at six weeks [2,26-28]. Reticulocytes increase and peak after 1 to 2

weeks [24,29], but the bone marrow may still be abnormal after three weeks [1,20].

Naturally acquired immunity to malaria (NAI) plays a role in limiting malaria-associated anaemia. In African children, the prevalence of anaemia, geometric mean parasite densities, and risk of fever with *P. falciparum* decrease with increasing age [30,31]. Consistent findings come from northeast Papua where, after approximately two years of intense malaria exposure, malaria naïve non-Papuan adults have similar malariometric indices (malaria prevalence rates, parasite densities, and malaria associated symptoms) as indigenous adult Papuans for *P. falciparum* but not for *P. vivax*. These data suggest the non-Papuan adults had acquired less protective immunity against *P. vivax* compared to *P. falciparum* [32,33].

There is a paucity of data on Hb dynamics and malaria-associated anaemia from NE Papua. Herein, a *post hoc* analysis of the Hb changes between malaria-immune, indigenous Papuans and non-Papuans from other parts of Indonesia with limited malaria exposure is reported.

Methods

The study took place from October 1995 to January 1998 at the Rumah Sakit Umum (RSU), a public hospital in Jayapura, the capital of Papua Province, Indonesia's most eastern province. Located on the northeast coast of Papua, Jayapura has low rates of malaria transmission but the surrounding lowland area is characterized by intense malaria transmission. Local malariometric data, study conduct and changes in the white blood cell and platelet counts in the same study patients have been detailed elsewhere [34-36]. Briefly, routine haematological parameters (Hb, total white cell and platelet counts) were measured and malaria films taken on Days (D) 0, 3, 7, and 28 during a trial of patients with acute symptomatic, uncomplicated vivax and falciparum malaria who were treated with either chloroquine (C) alone, chloroquine plus doxycycline (CD), or doxycycline (Dox) alone.

Parasite densities (N/ μ L) were calculated using the measured total white blood cell counts or assumed to be 8000/ μ L, if the white blood cell count was missing. Double entered and validated data (Epi Info 6.04b, Centers for Disease Control and Prevention, Atlanta, GA, USA) were analysed using Stata v8 (Stata Corporation, USA). Continuous data were compared by 't' test or one way ANOVA or the corresponding non-parametric tests, as appropriate. The relationship between two continuous variables was assessed by Pearson's correlation coefficient (r) and coefficient of determination (R^2) for normally distributed data or by Spearman Rho (skewed data). Proportions were compared by Chi-squared test or Fisher's exact test. Backward stepwise multiple regression was performed to assess the independence of




Figure 1 The mean haemoglobin concentrations at Day 0 and during following up, illustrating the total malaria attributable fall in haemoglobin (MAFt) and the malaria attributable haemoglobin fall before treatment (MAFbt).




Figure 2 Haemoglobin dynamics for all falciparum and all the vivax-infected patients.

variables on the Hb concentrations; adjusted (a) R^2 values are reported.

Written, informed consent was obtained from all patients. The study was conducted according to the Indonesian Ministry of Health, the Indonesian Navy, the United States Navy and US Army regulations governing the protection of human subjects.

Definitions

Anaemia of any degree was defined as Hb concentrations of <13 and <12 g/dL in males and females, respectively, and moderate anaemia as Hb <11 g/dL for both sexes, adapted from the WHO [37].

The mean total malaria attributable fall in Hb following treatment (MAFt) was defined as the difference between the mean D28 Hb in those successfully treated (i.e. patients without parasites on D28, Hb28wp) and the mean nadir Hb concentration which, in this study, was Day 3 for both species combined (Figure 1) and for each species (Figure 2). The mean malaria attributable fall in Hb before treatment (MAFbt) was defined as the mean Hb28wp minus the mean D0 Hb (Figure 1). The relative MAFt (MAFtrel) was expressed as a percentage of the baseline Hb.

Results

General characteristics

A total of 162 adult patients (Papuan = 57, non-Papuan = 105) were recruited: *Plasmodium vivax* (n = 63), *P. falciparum* (n = 89), and mixed infections (n = 10). These

were reclassified as *P. falciparum* (n = 9) and *P. vivax* (n = 1) based on which of the two species had the higher parasitaemia.

Males and females numbered 146 (15–44 years) and 16 (15–33y), respectively. Compared to the non-Papuan, the Papuan had a significantly longer: (i) median residential time, (ii) median time since the preceding episode of clinical malaria, (iii) duration of current illness, (iv) a higher spleen rate (by palpation), (v) a lower median vivax parasitaemia, and (vi) a higher rate of anaemia (Table 1).

Day 0 haemoglobin

Hb0 data were available for 152 patients. The mean (SD, range) D0 Hb concentration was 12.7 (2.2, 7–21.3) g/dL and was similar between the two species: *P. vivax* 12.9 (2.4) g/dL vs. *P. falciparum* 12.6 (2.1) g/dL ($P = 0.35$).

Significantly lower mean D0 Hb concentrations (Table 2) were found in: (i) vivax-infected Papuan vs. non-Papuan, (ii) all patients with splenomegaly (n = 47): 12.16 vs. 13.01 g/dL (without splenomegaly, n = 105): $\Delta = -0.85$ (-1.6 - -0.085), $P = 0.029$, and (iii) all females (n = 14) 10.18 vs. 13.01 g/dL (males, n = 138): [$\Delta = -2.82$ (-3.97 - -1.67), $P < 0.0001$].

There was a weak negative relationship between illness duration and D0 Hb ($R^2 = 0.04$) and no correlation between the D0 Hb and parasitaemias of both species ($P = 0.77$, $P = 0.54$). Multiple regression of the falciparum-infected patients identified female sex ($P = 0.000$) and illness duration ($P = 0.015$) as significant factors for a lower

Table 1 Demographic, clinical and laboratory characteristics of the Papuan and non-Papuan study subjects at disease presentation

	Papuans n = 57	Non Papuans n = 105	P
Age	22 (15–39)	24 (15–44)	0.0028
Male: Female	48 : 9	98 : 7	0.063
Residence in years	21.5 (15–39) y	3 (2m to 24) y	0.000
Previous clinical malaria**	2 (0–16)	3 (0–11)	0.15
Time since last malaria attack*	14w (8w–17m)	9w (6w–5.6m)	0.043
Duration of illness in days†	4 (1–30)	2 (1–30)	0.0003
Temperature‡	38 (36.5–41)	38.6 (36.1–41.3)	0.1
Splenomegaly	26 (45.6%)	27 (25.7%)	0.01
Anaemia§	34/52 (65.4%)	36/100 (36%)	0.001
Moderate anaemia¶	16/52 (30.8%)	20/100 (20%)	0.138
<i>P. falciparum</i> parasitaemia‡	3,007(20–64,998)	2,346 (38–74,432)	0.76
<i>P. vivax</i> parasitaemia‡	703 (55–9920)	2,592 (54–14124)	0.034

Continuous data are median (range) unless otherwise stated.

* number of previous malaria episodes by history.

† median (range).

§ Anaemia = haemoglobin < 13 g/dL (male), & 12 g/dL (female).

¶ Moderate anaemia = haemoglobin < 11 g/dL both sexes.

‡ median (range).

Table 2 Mean haemoglobin (standard deviation) and mean haemoglobin changes at follow up in Papuan and non-Papuan adults following treatment for *Plasmodium vivax* or *P. falciparum* malaria

	Papuans	N	Non Papuans	N	P
<i>Day 0</i>					
Hb	11.85 (1.88)	57	13.5 (2.27)	105	0.009
Males	12.27 (0.26)	44	13.35 (0.22)	94	0.005
Hb falciparum	12.16 (1.97)	36	12.94 (2.18)	53	0.1
Hb vivax	11.4 (1.59)	16	13.47 (2.35)	47	0.001
<i>Day 3</i>					
Hb	11.93 (2.02)	46	12.86 (1.73)	90	0.006
Hb falciparum	12.14 (2.12)	31	12.65 (1.83)	47	0.26
Hb vivax	11.5 (1.78)	15	13.09 (1.61)	43	0.0024
Δ Hb3 Hb0	-0.03 (-0.31 to +0.24)	46	-0.27 (-0.63 to +0.09)	90	0.39
Δ Hb3 Hb0 falciparum	-0.11 (-0.48 to +0.25)	31	-0.17 (-0.6 to +0.26)	47	0.85
Δ Hb3 Hb0 vivax	0.12 (-0.28 to +0.53)	15	-0.38 (-0.99 to +0.29)	43	0.33
<i>Day 7</i>					
Hb	12.2 (1.95)	43	12.8 (1.76)	83	0.1
Hb falciparum	12.28 (2.07)	29	12.3 (1.71)	40	0.96
Hb vivax	12.06 (1.75)	14	13.21 (1.71)	43	0.035
Δ Hb7 Hb0	0.31 (-0.05 to +0.68)	42	-0.23 (-0.71 to +0.12)	83	0.059
Δ Hb7 Hb0 falciparum	0.17 (-0.28 to +0.64)	28	-0.44 (-0.09 to +0.96)	40	0.09
Δ Hb7 Hb0 vivax	0.56 (-0.07 to +1.26)	14	-0.17 (-0.49 to +0.82)	43	0.2
<i>Day 28</i>					
Hb	13.07 (2.03)	27	13.9 (1.49)	47	0.038
Hb falciparum	13.23 (2.15)	19	13.49 (1.54)	25	0.64
Hb vivax	12.71 (1.79)	8	14.46 (1.28)	22	0.006
Δ Hb28 Hb0	1.15 (0.55 to 1.76)	26	0.94 (0.25 to 1.63)	47	0.66
Δ Hb28 Hb0 falciparum	1.06 (0.23 to 1.9)	18	1.2 (0.3 to 2.1)	25	0.82
Δ Hb28 Hb0 vivax	1.36 (0.46 to 2.26)	8	0.64 (-0.48 to 1.75)	22	0.44

D0 Hb. In the vivax-infected patients, being Papuan ($P = 0.017$) was the only significant variable; it was also associated with a lower D0 Hb.

Haemoglobin dynamics

For all patients combined, the mean Hb concentration fell to nadir on Day 3: -0.19 ($-9.4 - 4.2$) g/dL [$\equiv -0.55$ ($-44.1 - 44.7$) %]; this fall was inversely related to baseline Hb ($P = 0.000$, Additional file 1). By contrast, patients with baseline moderate anaemia had an initial rise on mean Hb (0.58 ($-1.2 - 4.2$) g/dL on D3) that was sustained to D28 (Figure 3).

For all patients combined, Hb dynamics were similar between the species (Figure 2), the falciparum infected Papuans (Figure 4), and the three drug arms (Additional file 2). The vivax-infected Papuans had a small mean rise in Hb by D3 (not significantly different to the small increase in the non-Papuans, $P = 0.33$) but had significantly

lower mean Hb concentrations on D3-28 compared to the non-Papuans with *P. vivax* (Table 2 and Figure 5).

By D28, the mean Hb ($n = 74$ patients) had risen significantly ($P = 0.0001$) to 13.6 g/dL and there was a corresponding fall ($P < 0.001$) in the proportion of anaemic patients to 29.73% ($22/74$) vs. baseline. The D28 Hb concentration was best explained by the D0 Hb concentration and sex (multiple regression): $aR^2 = 0.32$ ($P = 0.001$); removing sex from the model resulted in an $aR^2 = 0.24$ for D0 Hb.

Malaria attributable fall in haemoglobin

On Day 28, there were 65 patients who were parasite negative and had paired Hb3 and Hb28 data; their mean D28 Hb was 13.74 (SD 1.7 , range $9.9-18.1$) g/dL. The mean (range) MAFt and MAFrel values were 1.41 ($-1 - 5.6$) g/dL and 12.3 ($-8.5 - 62$) %, respectively. The mean MAFbt was 1.07 ($-7.9 - 6.2$) g/dL, representing




Figure 3 Haemoglobin dynamics for all patients combined as a function of baseline moderate anaemia (Hb <11 g/dL).

75.8% (1.07/1.41) of the MAFt. MAFt and MAFtrel gave essentially the same results in all analyses so MAFtrel results are reported hereafter.

In bivariate analyses, MAFtrel was significantly: (i) negatively correlated with the D0 Hb (Pearson's coefficient = -2.8, $P = 0.0001$), (ii) positively correlated with illness duration ($P = 0.0005$), (iii) higher ($P = 0.0005$) in patients with D0 moderate anaemia ($n = 16$) vs. those without moderate anaemia ($n = 49$): 23.3% vs. 6.6% (these %s correspond to MAFt concentrations of 1.9 vs. 0.9 g/L, (iv) higher ($P = 0.0067$) in patients with splenomegaly ($n = 24$) vs. those without splenomegaly ($n = 41$): 18.2% vs. 8.8% (MAFt concentrations of 2.03 vs. 1.05 g/L).

Non-significant MAFtrel factors included: (i) ethnicity: Papuan 10.9% vs. non-Papuan 13.1% ($P = 0.53$), (ii) drug

treatment ($P = 0.53$): 7.3% (C) vs. 12.6% (CD) vs. 13.7% (Dox), and sex ($P = 0.36$): 16.8% (female) vs. 11.7% (male).

Multivariate analysis in the falciparum infected patients ($aR^2 = 0.47$), identified four significant variables: Papuan ethnicity and D0 Hb were inversely correlated whilst illness duration and splenomegaly were positively correlated (Table 3). There were no explanatory variables in vivax patients ($aR^2 = 0$).

Discussion

This study has shown that, for all patients and when stratified by infecting species, haematological recovery was characterized by an initial fall in the mean Hb, followed by a rise, consistent with previous studies of falciparum and vivax malaria [2,38]. By contrast, patients




Figure 4 Haemoglobin dynamics in the falciparum infected Papuans and non-Papuans.




Figure 5 Haemoglobin dynamics in the vivax-infected Papuans and non-Papuans. The mean haemoglobin concentrations were significantly lower in the Papuans at each time point ($P \leq 0.035$), despite overlapping 95% confidence intervals.

with moderate anaemia had an initial rise in mean Hb, suggesting they had longer illness durations, had reached their nadir Hb at presentation and were “primed” to respond to anti-malarial treatment.

For all patients, the initial fall in mean Hb was modest, ~ 0.2 g/dL ($\sim 0.5\%$ vs. D0 Hb), and was inversely related to the baseline Hb. The subsequent increase in mean Hb, measured by the MAFt, was 1.4 g/dL; this figure compares favourably to the ~ 1.2 g/dL and ~ 1.1 g/dL in falciparum-infected patients of all ages from western Thailand [2] and Laotian adults [28], respectively, whose follow up was longer (42 days).

The MAFrel was used in these analyses as it might be better than the MAFt as marker of Hb recovery because it takes into account the baseline Hb. No independent factors were identified to explain the MAFrel in the vivax patients, suggesting inadequate patient numbers. For the falciparum patients, a higher MAFrel was associated with a lower D0 Hb, a longer illness duration and splenomegaly whereas a lower MAFrel was associated with being Papuan; these four factors accounted for just under half of the variance of the MAFrel. Interestingly,

Table 3 Multivariate analyses showing significant factors associated with the total malaria attributable fraction relative to the baseline haemoglobin in falciparum infected patients

Independent variable	Coefficient	95% CIs	P
Papuan ethnicity*	-6.41	-12.73 - -0.099	0.047
Day 0 haemoglobin†	-3.37	-4.95 - -1.79	0.000
Day 0 splenomegaly*	6.69	0.17 - 13.21	0.045
Illness duration§	0.71	0.073 - 1.34	0.030
Constant	49.53	29.02 - 70.04	0.000

No factors were identified in the vivax infected patients.

* dichotomous variable (present yes / no).

† Continuous variable measured in g/dL.

§ measured in days.

ethnicity was not significant in the bivariate analysis and when excluded from the multivariate analysis, the model was less good. Given that the falciparum infected Papuans had similar Hb dynamics as the non-Papuans; these statistical findings regarding the Papuans should be interpreted cautiously.

Longer illness duration and splenomegaly are factors associated with a lower D0 Hb which in turn is a stimulus for increased erythropoietin production. Thus, with treatment, the bone marrow response may be more robust as the suppressing effects of cytokines and haemozoin on it are reduced and as spleen size reduces, so red cell survival increases [1,22-24]. Although the bone marrow response appears more robust in patients with a lower baseline Hb, they did not “catch up” with the non-anaemic patients by study end. Furthermore, the D28 and D0 Hbs correlated positively (the latter explained $\sim 25\%$ of the D28 Hb variance). Therefore, “if you start low, you finish low”, despite better MAFrel values. Longer follow up would have given data on recovery times for the anaemic patients and may have shown, like Price *et al.* in Karen children and adults, that anaemic patient recover more slowly than those without anaemia [2]. Moderate anaemia (< 11 g/dL) was common ($\sim 23\%$) at presentation and is in broad agreement with 18% found in the Karen, using a haematocrit $< 30\%$ [2]. Factors associated with anaemia in the Karen were with age < 5 , splenomegaly, hepatomegaly, female sex, and prolonged illness, overlapping with some of the findings in the Papuan and non-Papuan adults.

The roles of ethnicity and NAI in the epidemiological context of NE Papuan are interesting questions. Data from this study suggest that the Papuans were haematologically disadvantaged when infected with *P. vivax*; they had persistently lower mean Hb concentrations post treatment compared to the non-Papuans. The indigenous Papuans had greater malaria exposure, because of their longer residence in Papua, suggesting that there may

have been differences in NAI between the two groups. Data from this area show there is divergence in the acquisition of NAI for the two main malaria species. NAI to *P. falciparum* develops after approximately two years of intense transmission in newly arriving non-Papuans [32,33]. The median residence time for non-Papuans in this study was 3 years; thus, half or more of them probably had similar degrees of NAI to *P. falciparum* as the Papuans. Similar degrees of NAI against *P. falciparum* probably explain the similar baseline parasitaemia and mean Hb concentrations from baseline to D28 despite the initial fall in mean Hb for the non-Papuans. By contrast, NAI to *P. vivax* takes longer to acquire and NAI was higher in the Papuans as evidenced by their significantly lower median, baseline vivax parasitaemia; however, their vivax related NAI was not haematologically beneficial.

The Papuan haematological conundrum is unexplained and might represent host factors like G6PD deficiency, ovalocytosis, HIV, iron deficiency or pathophysiological factor/s unique to the Papuans that operate more in *P. vivax* infections, e.g. greater red cell fragility/splenic destruction, more cytokine induced bone marrow suppression, slower bone marrow recovery. These speculations underscore the lack of knowledge of the mechanisms of Hb dynamics in these two populations and call for further detailed investigation [39].

This study has several limitations. The analyses were supplementary to those of a small clinical trial of 162 adult patients and follow up was 28 days, two weeks before Hb stabilizes. By contrast, Price *et al.* analysed ~1,500 adults and children over 63 days [2]. The study herein reported was not designed *a priori* to detail the haematological responses; thus, key haematological parameters like the mean corpuscular volume, reticulocyte counts, iron metabolic parameters, G6PD status, presence of thalassaemia and ovalocytosis were not tested. Such data would be essential in a haematological investigation in ethnically diverse NE Papua.

To conclude, this study has shown similar Hb dynamics between vivax and falciparum malaria but unexplained differences between vivax-infected Papuans and non-Papuans.

Additional files

Additional file 1: The relationship between the absolute change in the initial fall (hbdiff30) in haemoglobin on Day 3 and the baseline haemoglobin concentration (hb0) in g/dL for the Papuans and non-Papuans combined.

Additional file 2: Box plots of haemoglobin dynamics as a function of treatment arms in all patients with both species. C = chloroquine alone, CD = chloroquine plus doxycycline, Dox = doxycycline alone.

Competing interest

None of the authors have a conflict of interest.

Authors' contributions

CO conceived the original design. CO, WRJT, ET, SLH, TLR developed the protocol. WRJT, HW, HB, Taufik, ET, SB executed the study. WRJT analysed the data and wrote the first draft of the paper. TLR, SLH, CO, ET contributed significantly to revisions of the paper. All authors read and approved the final manuscript.

Acknowledgments

We are grateful to the patients for joining this study. The authors wish to thank the following for their contribution to the study: (i) the nurses at the Jayapura General Hospital and the Indonesian Naval Hospital (ii) Drs. Oyong (Jayapura General Hospital) and Kristanto (Indonesian Naval Hospital) for their support in study execution, (iii) Nona Nurjaya Kadir and Pak Ferryanto C. Sanggamelefor slide reading, laboratory work, and data management, (iv) Pak Purnomo Prodjodipuro, Sofyan Masbar, Awalludin Sutamiharja and Pak Suradi for slide reading (v) Dr. Budi Subianto, (Provincial Health Office, Jayapura) for facilitating study execution, (vi) Dr. Kasia Stepniewska for helping WRJT with some of the statistics. CO, SLH and TLR were active duty United States military personnel at the time they contributed to this work; HW and HB were Foreign Service nationals working for the US Government; and WRJT was an Intergovernmental Personnel Act employee working for the US Government. The work of these individuals was prepared as part of official government duties. Title 17 U.S.C. §101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S. Government as part of that person's official duties. Title 17 U.S.C. §105 provides that 'Copyright protection under this title is not available for any work of the United States Government.' The work of authors affiliated with the US Naval Medical Research Unit #2 was supported by work unit number DoD 63002A M00101 HEX 2406. The study protocol for the clinical research presented in this manuscript was approved by the NAMRU-2 and Indonesian Ministry of Health Institutional Review Boards, in compliance with all applicable Federal regulations governing protection of human subjects. All study subjects gave written informed consent. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Indonesian Military, the Indonesian Ministry of Health, the US Department of the Navy, the US Department of the Army, the US Department of Defense, or the U.S. Government.

Funding

This study was funded by the US Naval Medical Research and Development Command (DoD 63002A M00101 HEX 2406).

Disclaimer

The views expressed in this paper are the authors' and do not in any way represent those of the Indonesian Navy, the Indonesian Ministry of Health, or the US Navy.

Author details

¹The US Navy Medical Research Unit no. 2 (NAMRU-2), Jakarta, Indonesia. ²Department of Tropical Medicine, Tulane University School of Public Health, New Orleans, USA. ³Centre for Health Research and Development, National Institutes of Health, Jakarta, Indonesia. ⁴Armed Forces Research Institute of Medical Science, Bangkok, Thailand. ⁵Indonesian Naval Hospital, Jayapura, Papua, Indonesia. ⁶Rumah Sakit Umum, Jayapura, Papua, Indonesia. ⁷Naval Medical Research Center, Bethesda, MD, USA.

Received: 4 January 2013 Accepted: 5 June 2013

Published: 19 June 2013

References

1. Wickramasinghe SN, Abdalla SH: **Blood and bone marrow changes in malaria.** *Baillieres Best Pract Res Clin Haematol* 2000, **13**:277–299.
2. Price RN, Simpson JA, Nosten F, Luxemburger C, Hkirjaroen L, ter Kuile F, Chongsuphajaisiddhi T, White NJ: **Factors contributing to anaemia after uncomplicated falciparum malaria.** *Am J Trop Med Hyg* 2001, **65**:614–622.
3. Bruneel F, Gachot B, Wolff M, Regnier B, Danis M, Vachon F: **Resurgence of blackwater fever in long-term European expatriates in Africa: report of 21 cases and review.** *Clin Infect Dis* 2001, **32**:1133–1140.
4. van Eijk AM, Ayisi JG, Ter erKuile FO, Misore AO, Otiemo JA, Kolczak MS, Kager PA, Steketee RW, Nahlen BL: **Malaria and human immunodeficiency**

- virus infection as risk factors for anemia in infants in Kisumu, western Kenya. *Am J Trop Med Hyg* 2002, **67**:44–53.
5. Dreyfuss ML, Stoltzfus RJ, Shrestha JB, Pradhan EK, LeClerq SC, Khatry SK, Shrestha SR, Katz J, Albonico M, West KP Jr: **Hookworms, malaria and vitamin A deficiency contribute to anemia and iron deficiency among pregnant women in the plains of Nepal.** *J Nutr* 2000, **130**:2527–2536.
 6. Looareesuwan S, Davis TM, Pukrittayakamee S, Supanaranond W, Desakorn V, Silamut K, Krishna S, Boonamrung S, White NJ: **Erythrocyte survival in severe falciparum malaria.** *Acta Trop* 1991, **48**:263–270.
 7. Anstey NM, Russell B, Yeo TW, Price RN: **The pathophysiology of vivax malaria.** *Trends Parasitol* 2009, **25**:220–227.
 8. Hue NT, Charlieu JP, Chau TT, Day N, Farrar JJ, Hien TT, Dunstan SJ: **Glucose-6-phosphate dehydrogenase (G6PD) mutations and haemoglobinuria syndrome in the Vietnamese population.** *Malar J* 2009, **8**:152.
 9. Luzzatto L: **The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics.** *Lancet* 2010, **376**:739–741.
 10. Collins WE, Jeffery GM, Roberts JM: **A retrospective examination of anemia during infection of humans with *Plasmodium vivax*.** *Am J Trop Med Hyg* 2003, **68**:410–412.
 11. Jakeman GN, Saul A, Hogarth WL, Collins WE: **Anaemia of acute malaria infections in non-immune patients primarily results from destruction of uninfected erythrocytes.** *Parasitology* 1999, **119**(Pt 2):127–133.
 12. Looareesuwan S, Ho M, Wattanagoon Y, White NJ, Warrell DA, Bunnag D, Harinasuta T, Wyler DJ: **Dynamic alteration in splenic function during acute falciparum malaria.** *N Engl J Med* 1987, **317**:675–679.
 13. Anyona SB, Schrier SL, Gichuki CW, Waitumbi JN: **Pitting of malaria parasites and spherocyte formation.** *Malar J* 2006, **5**:64.
 14. Lamikanra AA, Brown D, Potocnik A, Casals-Pascual C, Langhorne J, Roberts DJ: **Malarial anemia: of mice and men.** *Blood* 2007, **110**:18–28.
 15. Dondorp AM, Nyanoti M, Kager PA, Mithwani S, Vreeken J, Marsh K: **The role of reduced red cell deformability in the pathogenesis of severe falciparum malaria and its restoration by blood transfusion.** *Trans R Soc Trop Med Hyg* 2002, **96**:282–286.
 16. Dondorp AM, Angus BJ, Chotivanich K, Silamut K, Ruangveerayuth R, Hardeman MR, Kager PA, Vreeken J, White NJ: **Red blood cell deformability as a predictor of anemia in severe falciparum malaria.** *Am J Trop Med Hyg* 1999, **60**:733–737.
 17. Handayani S, Chiu DT, Tjitra E, Kuo JS, Lampah D, Kenangalem E, Renia L, Snounou G, Price RN, Anstey NM, Russell B: **High deformability of *Plasmodium vivax*-infected red blood cells under micro fluidic conditions.** *J Infect Dis* 2009, **199**:445–450.
 18. Angus BJ, Chotivanich K, Udomsangpetch R, White NJ: **In vivo removal of malaria parasites from red blood cells without their destruction in acute falciparum malaria.** *Blood* 1997, **90**:2037–2040.
 19. Newton PN, Chotivanich K, Chierakul W, Ruangveerayuth R, Teerapong P, Silamut K, Looareesuwan S, White NJ: **A comparison of the in vivo kinetics of *Plasmodium falciparum* ring-infected erythrocyte surface antigen-positive and -negative erythrocytes.** *Blood* 2001, **98**:450–457.
 20. Phillips RE, Looareesuwan S, Warrell DA, Lee SH, Karbwang J, Warrell MJ, White NJ, Swasdichai C, Weatherall DJ: **The importance of anaemia in cerebral and uncomplicated falciparum malaria: role of complications, dyserythropoiesis and iron sequestration.** *Q J Med* 1986, **58**:305–323.
 21. Clark IA, Chaudhri G: **Tumour necrosis factor may contribute to the anaemia of malaria by causing dyserythropoiesis and erythrophagocytosis.** *Br J Haematol* 1988, **70**:99–103.
 22. Othoro C, Lal AA, Nahlen B, Koech D, Orago AS, Udhayakumar V: **A low interleukin-10 tumor necrosis factor-alpha ratio is associated with malaria anemia in children residing in a holoendemic malaria region in western Kenya.** *J Infect Dis* 1999, **179**:279–282.
 23. Casals-Pascual C, Kai O, Cheung JO, Williams S, Lowe B, Nyanoti M, Williams TN, Maitland K, Molyneux M, Newton CR, Peshu N, Watt SM, Roberts DJ: **Suppression of erythropoiesis in malarial anemia is associated with hemozoin in vitro and in vivo.** *Blood* 2006, **108**:2569–2577.
 24. Kurtzhals JA, Rodrigues O, Addae M, Commey JO, Nkrumah FK, Hviid L: **Reversible suppression of bone marrow response to erythropoietin in *Plasmodium falciparum* malaria.** *Br J Haematol* 1997, **97**:169–174.
 25. Burgmann H, Looareesuwan S, Kapiotis S, Viravan C, Vanijanonta S, Hollenstein U, Wiesinger E, Presterl E, Winkler S, Graninger W: **Serum levels of erythropoietin in acute *Plasmodium falciparum* malaria.** *Am J Trop Med Hyg* 1996, **54**:280–283.
 26. Nussenblatt V, Mukasa G, Metzger A, Ndeezee G, Garrett E, Semba RD: **Anemia and interleukin-10, tumor necrosis factor alpha, and erythropoietin levels among children with acute, uncomplicated *Plasmodium falciparum* malaria.** *Clin Diagn Lab Immunol* 2001, **8**:1164–1170.
 27. Camacho LH, Gordeuk VR, Wilairatana P, Pootrakul P, Brittenham GM, Looareesuwan S: **The course of anaemia after the treatment of acute, falciparum malaria.** *Ann Trop Med Parasitol* 1998, **92**:525–537.
 28. Mayxay M, Khanthavong M, Lindegardh N, Keola S, Barends M, Pongvongsa T, Yapom R, Annerberg A, Phompida S, Phetsouvanh R, White NJ, Newton PN: **Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic.** *Clin Infect Dis* 2004, **39**:1139–1147.
 29. Srichaikul T, Panikbutr N, Jeumtrakul P: **Bone-marrow changes in human malaria.** *Ann Trop Med Parasitol* 1967, **61**:40–51.
 30. Premji Z, Hamisi Y, Shiff C, Minjas J, Lubega P, Makwaya C: **Anaemia and *Plasmodium falciparum* infections among young children in an holoendemic area, Bagamoyo, Tanzania.** *Acta Trop* 1995, **59**:55–64.
 31. Bloland PB, Boriga DA, Ruebush TK, McCormick JB, Roberts JM, Oloo AJ, Hawley W, Lal A, Nahlen B, Campbell CC: **Longitudinal cohort study of the epidemiology of malaria infections in an area of intense malaria transmission II. Descriptive epidemiology of malaria infection and disease among children.** *Am J Trop Med Hyg* 1999, **60**:641–648.
 32. Baird JK, Purnomo, Basri H, Bangs MJ, Andersen EM, Jones TR, Masbar S, Harjosuwarno S, Subianto B, Arbani PR: **Age-specific prevalence of *Plasmodium falciparum* among six populations with limited histories of exposure to endemic malaria.** *Am J Trop Med Hyg* 1993, **49**:707–719.
 33. Baird JK, Jones TR, Danudirgo EW, Annis BA, Bangs MJ, Basri H, Purnomo, Masbar S: **Age-dependent acquired protection against *Plasmodium falciparum* in people having two years exposure to hyperendemic malaria.** *Am J Trop Med Hyg* 1991, **45**:65–76.
 34. Taylor WR, Widjaja H, Richie TL, Basri H, Ohrt C, Tjitra, Taufik E, Jones TR, Kain KC, Hoffman SL: **Chloroquine/doxycycline combination versus chloroquine alone, and doxycycline alone for the treatment of *Plasmodium falciparum* and *Plasmodium vivax* malaria in northeastern Irian Jaya, Indonesia.** *Am J Trop Med Hyg* 2001, **64**:223–228.
 35. Taylor WR, Widjaja H, Basri H, Ohrt C, Taufik T, Tjitra E, Baso S, Fryauff D, Hoffman SL, Richie TL: **Changes in the total leukocyte and platelet counts in Papuan and non-Papuan adults from northeast Papua infected with acute *Plasmodium vivax* or uncomplicated *Plasmodium falciparum* malaria.** *Malar J* 2008, **7**:259.
 36. Jones TR, Baird JK, Basri H, Purnomo, Danudirgo EW: **Prevalence of malaria in native and transmigrant populations. Effects of age and history of exposure.** *Trop Geogr Med* 1991, **43**:1–6.
 37. WHO: **Iron deficiency anaemia: assessment, prevention and control: a guide for programme managers.** Geneva: World Health Organization; 2001.
 38. Poravuth Y, Socheat D, Rueangweerayut R, Uthaisin C, Pyae Phy A, Valecha N, Rao BH, Tjitra E, Purnama A, Borghini-Fuhrer I, Duparc S, Shin CS, Fleckenstein L: **Pyronaridine-artesunate versus chloroquine in patients with acute *Plasmodium vivax* malaria: a randomized, double-blind, non-inferiority trial.** *PLoS One* 2011, **6**:e14501.
 39. Douglas NM, Anstey NM, Buffet PA, Poespoprodjo JR, Yeo TW, White NJ, Price RN: **The anaemia of *Plasmodium vivax* malaria.** *Malar J* 2012, **11**:135.

doi:10.1186/1475-2875-12-209

Cite this article as: Taylor et al.: Haemoglobin dynamics in Papuan and non-Papuan adults in northeast Papua, Indonesia, with acute, uncomplicated vivax or falciparum malaria. *Malaria Journal* 2013 **12**:209.